Bortezomib induces clinical remission and reduction of ADAMTS13 inhibitory antibodies in relapsed refractory idiopathic thrombotic thrombocytopenic purpura

Br J Haematol. 2014 Mar;164(6):900-2. doi: 10.1111/bjh.12696. Epub 2013 Dec 17.
No abstract available

Keywords: bortezomib; thrombotic haemolytic anaemias; thrombotic thrombocytopenic purpura.

Publication types

  • Case Reports
  • Letter

MeSH terms

  • ADAM Proteins / antagonists & inhibitors
  • ADAM Proteins / immunology*
  • ADAMTS13 Protein
  • Antineoplastic Agents / therapeutic use*
  • Autoantibodies / immunology*
  • Autoantibodies / metabolism
  • Boronic Acids / therapeutic use*
  • Bortezomib
  • Female
  • Humans
  • Middle Aged
  • Purpura, Thrombotic Thrombocytopenic / drug therapy*
  • Purpura, Thrombotic Thrombocytopenic / immunology
  • Purpura, Thrombotic Thrombocytopenic / pathology
  • Pyrazines / therapeutic use*
  • Recurrence
  • Remission Induction

Substances

  • Antineoplastic Agents
  • Autoantibodies
  • Boronic Acids
  • Pyrazines
  • Bortezomib
  • ADAM Proteins
  • ADAMTS13 Protein
  • ADAMTS13 protein, human

Supplementary concepts

  • Thrombotic thrombocytopenic purpura, acquired